German biomedical company ARTCLINE has closed a €5 million convertible loan financing round to complete its ongoing ReActIF-ICE clinical trial evaluating the ARTICE® extracorporeal therapy. The treatment uses allogeneic immune cells from healthy donors to support dysregulated immune systems in septic shock patients.

ARTCLINE GmbH, a German biomedical company developing novel immune cell therapies for septic shock, has successfully secured €5 million in convertible loan financing to advance its innovative ARTICE therapy through clinical evaluation and towards market launch.

The Rostock-based company announced on 9 September that the funding round received strong support from both existing and new investors. The capital will be used to complete and evaluate the ongoing randomised, controlled multicentre ReActIF-ICE study (NCT05442710), which is investigating the clinical benefits of ARTCLINE’s patented extracorporeal therapy for treating immune dysfunction in septic shock patients.

Clinical trial expected to complete in early 2026

The ReActIF-ICE study is expected to be completed in the first quarter of 2026, according to Managing Director Dirk Hessel. “We are delighted with the great confidence our investors are placing in ARTCLINE by supporting this crucial phase of the company’s development,” Hessel commented. “This financing secures the finalization and evaluation of the ReActIF-ICE study, which is expected to be completed in the first quarter of 2026.”

The ARTICE therapy addresses a significant clinical challenge in septic shock management. While patients may survive the initial acute phase of septic shock, subsequent immune dysfunction often leads to fatal secondary infections or organ failure. The therapy uses allogeneic immune cells from healthy donors to temporarily support key functions of the patient’s dysregulated immune system and help restore immune activity.

Addressing a global health challenge

Managing Director and founder Jens Altrichter emphasised the therapy’s clinical relevance: “Sepsis is one of the leading causes of death worldwide, accounting for one in five fatalities. While patients may survive the initial phase of septic shock, the subsequent immune dysfunction often leads to fatal secondary infections or organ failure. This is exactly where the ARTICE therapy is administered.”

The extracorporeal treatment was developed through collaboration between immunologists and dialysis specialists, representing a novel approach to managing the complex immune dysfunction that characterises septic shock.

For more information, visit: www.artcline.de